236L细胞
数量： 大量
细胞形态： **样
**类型： IgG1; kappa light chain
ATCC Number： HB-12593™
运输方式： 冻存运输
生长状态： 悬浮生长
是否是肿瘤细胞： 0
物种来源： 小鼠
Designations: 236L
Depositors: ICOS Corporation
Isotype: IgG1; kappa light chain
236L细胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Cellular Products: immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 236L细胞(alphaDbeta2) integrin
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with purified rat alphaD subunit. [56177]
Spleen cells were fused with NS-1 mouse myeloma cells.
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Propagation: 236L细胞ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO
References: 56177: Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001
57779: Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. 236L细胞PubMed: 11031083
